Docket No. 3128 4906

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	(s): EMALFARB, et al. 195								
r r	(s): EMALFARB, et al. OF Group Art 1639								
Serial No.	: 09/834,434 ( oct 0 9 2003 %)								
Filed:	April 13, 2001  RADEMIC TEXAMENT TERES D. WESSENDORF								
For:	HIGH-THROUGHPUT SCREENING OF EXPRESSED DNA LIBRARIES IN FILAMENTOUS FUNGI								
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT									
P.O. Box	oner for Patents								
Sir:									
This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97									
and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record									
to assist th	e Patent and Trademark Office in its examination of this application. The Examiner is								
respectfull	ly requested to fully consider the items and to independently ascertain their teaching.								
	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:								
	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.								
3.	Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not								

No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed

37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or

Docket No. <u>3123-4006</u> Serial No. <u>09/834,434</u>

		37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
	$\boxtimes$	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
		37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.	since in para Allow	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified agraph 4 above but before the mailing date of a final action or a Notice of ance (where there has been no prior final action), and is accompanied by one of rtifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6.	it is be	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(c), after the period specified in raph 4 above but before the mailing date of a final action or a notice of unce (where there has been no prior final action):
		A check in the amount of \$180.00 is enclosed in payment of the fee.
		Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7.	it is be action	is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since sing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a fina or a notice of allowance, whichever comes first, but before payment of the issued is accompanied by:
		ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and
		e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 clow.

Docket No. <u>3123-4006</u> Serial No. <u>09/834,434</u>

8.	Ш	This Information Disclosure Statement is being filed in compliance with:
		a.   37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
		b. 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
		c. The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.
9.		I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
		I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10.	$\boxtimes$	This document is accompanied by \( \subseteq \) a Search Report \( \subseteq \) Communication which was cited in a corresponding \( \subseteq \) PCT or \( \subseteq \) Foreign counterpart application
11.		A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
		Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Docket No. <u>3123-4006</u> Serial No. <u>09/834,434</u>

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. <u>13-4500</u>, Order No. <u>3123-4006</u>. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

By:

Respectfully submitted, MORGAN & FINNEGAN, L.L.P.

Dated: October 9, 2003

Sybil A. Lombillo

Registration No. 54,280

Correspondence Address: MORGAN & FINNEGAN, L.L.P. 345 Park Avenue

New York, NY 10154-0053 (212) 758-4800 Telephone

(212) 751-6849 Facsimile

OCT 0 9 2003

Docket No. <u>3123-4006</u> Serial No. <u>09/834,434</u>

The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3123-4006. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted, MORGAN & FINNEGAN, L.L.P.

Dated: October 9, 2003

By:

Sybil A. Lombillo Registration No. 54,280

Correspondence Address: MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, NY 10154-0053 (212) 758-4800 Telephone (212) 751-6849 Facsimile OCT 0 9 2003

		Page 1 of 1
mey Docket:	Serial No.:	

RADEMARY **FORM PTO-1449** 

INFORMATION DISCLOSURE CITATION

Attorney Docket: 3/23-4006 09/834,434

Applicant: EMALFARB, et al.

Filing Date: April 13, 2001

Group Art Unit: 1639

			U.S. PA	TENT	DOCUMENTS					
Examiner Initial		Patent Number	Issue Date		Name	Class	Sub-Clas	s	Filing Date	
	1	4,816,405	March 28, 1989  July 16, 1996  November 26, 1996		Yelton et al.	435	254.3 M		October 16, 1987	
	2	5,536,661			Boel et al.	435			March 7, 1994	
	3	5,578,463			Berka et al.	435			August 2, 1994	
							REC	FIL	/n_	
		-					PEC OCT 1	6 200	₹D	
					h.	TEC	OCT I H CENTER	1600/	12900	
				PATE	NT DOCUMENTS					
Examiner Initial		Patent Number	Publication Date		Country			Sub- Class_	Translation	
									☐ Yes ☐ No	
									☐ Yes ☐ No	
									☐ Yes ☐ No	
									☐ Yes ☐ No	
	···								☐ Yes ☐ No	
		OTHE	R DOCUMENT	S (Incl	uding Author, Title,	Date, etc.)				
					•					
				. <del></del>						
Examiner	ļ			Da	ite Considered					
	Draw line	eference considered, whether through citation if not in co py of this form with next co	nformance and not c	onsidered						